June 3, 2020
Asahi Kasei Pharma said on June 2 that its dysuria treatment Flivas (naftopidil) was granted approval by Chinese regulators on May 20. The drug is an α1-adrenergic receptor antagonist used to treat dysuria associated with benign prostatic hypertrophy. In China,...read more